핵의학

본문글자크기
  • [Cancer Res.] Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3′-Deoxy-3′-[18F]Fluorothymidine in Preclinical Models of Lung Cancer

    European Institute for Molecular Imaging / Andreas H. Jacobs*

  • 출처
    Cancer Res.
  • 등재일
    2016 Dec 15
  • 저널이슈번호
    76(24):7096-7105. Epub 2016 Oct 26.
  • 내용

    바로가기  >

    Abstract

    3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography ([18F]FLT-PET) and diffusion-weighted MRI (DW-MRI) are promising approaches to monitor tumor therapy response. Here, we employed these two imaging modalities to evaluate the response of lung carcinoma xenografts in mice after gemcitabine therapy. Caliper measurements revealed that H1975 xenografts responded to gemcitabine treatment, whereas A549 growth was not affected. In both tumor models, uptake of [18F]FLT was significantly reduced 6 hours after drug administration. On the basis of the gemcitabine concentration and [18F]FLT excretion measured, this was presumably related to a direct competition of gemcitabine with the radiotracer for cellular uptake. On day 1 after therapy, [18F]FLT uptake was increased in both models, which was correlated with thymidine kinase 1 (TK1) expression. Two and 3 days after drug administration, [18F]FLT uptake as well as TK1 and Ki67 expression were unchanged. A reduction in [18F]FLT in the responsive H1975 xenografts could only be noted on day 5 of therapy. Changes in ADCmean in A549 xenografts 1 or 2 days after gemcitabine did not seem to be of therapy-related biological relevance as they were not related to cell death (assessed by caspase-3 IHC and cellular density) or tumor therapy response. Taken together, in these models, early changes of [18F]FLT uptake in tumors reflected mechanisms, such as competing gemcitabine uptake or gemcitabine-induced thymidylate synthase inhibition, and only reflected growth-inhibitory effects at a later time point. Hence, the time point for [18F]FLT-PET imaging of tumor response to gemcitabine is of crucial importance. 

     

    Author information

    Schelhaas S1, Held A1, Wachsmuth L2, Hermann S1, Honess DJ3, Heinzmann K3, Smith DM3, Griffiths JR3, Faber C2, Jacobs AH4,5.

    1European Institute for Molecular Imaging (EIMI), Westfälische Wilhelms-Universität (WWU) Münster, Münster, Germany.

    2Department of Clinical Radiology, University Hospital of Münster, Münster, Germany.

    3Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.

    4European Institute for Molecular Imaging (EIMI), Westfälische Wilhelms-Universität (WWU) Münster, Münster, Germany. ahjacobs@uni-muenster.de.

    5Department of Geriatric Medicine, Johanniter Hospital, Bonn, Germany.

     

  • 덧글달기
    덧글달기
       IP : 3.144.127.232

    등록